Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma ; volume:82 ; number:2 ; day:25 ; month:6 ; year:2018 ; pages:353-360 ; date:8.2018
Cancer chemotherapy and pharmacology ; 82, Heft 2 (25.6.2018), 353-360, 8.2018
- Creator
-
Fruehauf, John P.
- Contributor
-
El-Masry, Monica
Osann, Katherine
Parmakhtiar, Basmina
Yamamoto, Maki
Jakowatz, James G.
SpringerLink (Online service)
- DOI
-
10.1007/s00280-018-3624-6
- URN
-
urn:nbn:de:101:1-2018092421092963370656
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fruehauf, John P.
- El-Masry, Monica
- Osann, Katherine
- Parmakhtiar, Basmina
- Yamamoto, Maki
- Jakowatz, James G.
- SpringerLink (Online service)
Other Objects (12)
Reversible Hypopigmentation with Pazopanib
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
Meningioma with Metastatic Malignant Melanoma: An Unusual Coincidence
GNAQmutation in a patient with metastatic mucosal melanoma
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Reversible Hypopigmentation with Pazopanib
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
Meningioma with Metastatic Malignant Melanoma: An Unusual Coincidence
GNAQmutation in a patient with metastatic mucosal melanoma
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Reversible Hypopigmentation with Pazopanib
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
Meningioma with Metastatic Malignant Melanoma: An Unusual Coincidence
GNAQmutation in a patient with metastatic mucosal melanoma
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma